Lupin could face FDA regulatory action over Tarapur API facility13 Jan 2020
India’s Lupin Pharmaceuticals warned Monday it could face regulatory sanctions from the US Food and Drug Administration over its Tarapur active pharmaceutical ingredient (API) manufacturing facility.
“The company has received a communication from the US FDA classifying the inspection conducted at its Tarapur manufacturing (API) facility between September 16 to September 20, 2019 as Official Action Indicated,” Lupin said in a filing to the Bombay Stock Exchange.
According to the FDA’s official definition, an OIA means that “objectional conditions were found and regulatory administrative sanctions by FDA are indicated.”
Lupin said in the filing it did not believe that the inspection classification would have an impact on disruption of supplies or the existing revenues from operations of the facility.
“The company is in the process of sending further updates of its corrective actions to the US FDA and is hopeful of a positive outcome,” Lupin said.
Back in October, the FDA issued a Form 483 listing three observations of violations of current good manufacturing practices (cGMP) at the Tarapur plant.
In the letter, the FDA said Lupin had failed to maintain batch production and control records and not carried out a satisfactory review of unexplained discrepancies “whether or not the batch has already been distributed.”
The FDA also cited failure by workers at the plant “to handle and store cleaned utensils in a manner to prevent contamination.”
Separately in another exchange filing on January 11, Lupin said the FDA had completed a Prior Approval Inspection at its Nagpur oral solid dosage manufacturing facility between January 6 and January 10, closing with 483 observations.
Lupin managing director, Nilesh Gupta said the company was committed to meeting the highest quality standards and to full compliance with current good manufacturing practice regulations at all its manufacturing facilities.
“We will address the observations raised by the agency satisfactorily and will submit our comprehensive response within the stipulated timeline,” he added.
Pioneer in Phenylketonuria to begin clinical trial with gene therapy
15 Jan 2020
BMN 307 represents a potential third PKU treatment option from BioMarin and its second gene therapy clinical program.Read more
Catalent launches direct-to-patient clinical supply services
14 Jan 2020
Multiple options provide increased flexibility for sponsors.Read more
Biogen to acquire novel clinical-stage asset from Pfizer
14 Jan 2020
PF-05251749 complements the company’s pipeline of potential disease-modifying therapies for Alzheimer’s and Parkinson’s diseases.Read more
French regulator agrees to partial resumption of Tellomak trial patient recruitment
14 Jan 2020
The French National Agency for Medicines and Health Product Safety (ANSM) has agreed that Innate Pharma’s Tellomak (lacutamab) Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) in ...Read more
Partnership formed to develop and commercialise ready-to-use medicine
13 Jan 2020
The product being developed will use proprietary drug formulation technology platform Arestat to deliver new reformulations of existing, complex products.Read more
ReadCoor to commercially launch spatial sequencing platform
10 Jan 2020
Platform gives researchers access to previously undiscovered data to guide evaluation and validation of new drug targets, pathogen identification, disease diagnosis, and the advancement of regenerative medicine.Read more
CPhI and AAPS partner to expand expert scientific content at CPhI North America
10 Jan 2020
CPhI and the American Association of Pharmaceutical Scientists (AAPS) today announced a partnership to expand the scientific content of activities sponsored by CPhI, including CPhI North America—the only event to bring the entire North American pharmac...Read more
Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API
9 Jan 2020
The US arm of generic and specialty pharma company Mylan Pharmaceuticals has recalled three lots of its heartburn drug Nizatidine in capsule form amid fears of possible nitrosamine contamination.Read more
New HQ for developer of world's first fully automated drug discovery platform
8 Jan 2020
End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.Read more
Catalent completes purchase of biologics fill-finish and oral solid dose facility
7 Jan 2020
Facility provides European customers with great biologics and oral dose capabilities that can help reduce time-to-market.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation